

10021994

**IMPRA**

A Subsidiary of C. R. Bard, Inc.  
1625 West 3rd Street  
P.O. Box 1740  
Tempe, AZ 85280-1740  
TEL: 800-321-4254  
480-894-9515  
FAX: 480-966-7062

JAN 02 2002



**510(k) SUMMARY OF  
SAFETY AND EFFECTIVENES INFORMATION**

**A. Submitter Information:**

Submitter's Name: Impra, Inc.  
Submitter's Address: 1625 West 3<sup>rd</sup> Street  
Tempe, AZ 85281  
Contact Person: Aymee Berry  
Contact Person's Telephone Number: (480) 303-2752  
Contact Person's FAX Number: (480) 449-2546  
Date of Preparation: June 12, 2002

**B. Device Name:**

Bard® CONFORMEXX™ Biliary Stent and Delivery System

**C. Predicate Device:**

Bard® memotherm-FLEXX™ Biliary Stent  
Bard® memotherm Transhepatic Biliary Endoprosthesis  
Bard® LUMINEXX™ 6 Fr Delivery System

**D. Device Description:**

The Bard® CONFORMEXX™ Biliary Stent and Delivery System is a stenting device designed to maintain the patency of biliary ducts obstructed by malignant neoplasms. The device includes the self-expanding Bard® CONFORMEXX™ Biliary Stent pre-loaded on a unique delivery system. The stent is available in a variety of diameters and lengths.

The 6 Fr delivery system is compatible with a 6 Fr introducer and accepts a 0.018" to 0.035" guidewire. The delivery systems is 135cm in length.



E. Intended Use:

The Bard® CONFORMEXX™ Biliary Stent and Delivery System is indicated for use in the treatment of biliary strictures resulting from malignant neoplasms.

F. Technological Characteristics Summary:

The Bard® CONFORMEXX™ Biliary Stent is a metal mesh stent constructed of nitinol. The nitinol tube is laser cut into a series of rhombi.

The flexibility of the Bard® CONFORMEXX™ Delivery System allows for smooth trackability and accurate stent placement.

G. Performance Data:

The Bard® CONFORMEXX™ Biliary Stent tracks easily from the delivery system, even in a tortuous path. Accuracy of placement, expansion and compression force test results are comparable to those of the predicate devices. The stent is resistant to corrosion by bile.

The delivery system bond joint tensile strengths vary depending on the bond location but are comparable to those of the predicate device.



JAN 2 - 2003

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Aymee R. Berry  
Senior Regulatory Affairs Specialist  
C.R. Bard, Inc., Division of IMPRA, Inc.  
1625 West 3<sup>rd</sup> Street  
TEMPE AZ 85281

Re: K021994

Trade/Device Name: Bard® CONFORMEXX™ Biliary Stent and Delivery System  
Regulation Number: 21 CFR §876.5010  
Regulation Name: Biliary catheter and accessories  
Regulatory Class: II  
Product Code: 78 FGE  
Dated: October 2, 2002  
Received: October 3, 2002

Dear Ms. Berry:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:

The safety and effectiveness of this device for use in the vascular system have not been established.

Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.

Page 2 – Ms. Aymee R. Berry

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement above is added to your labeling, as described.

Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.

If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801 and additionally Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4616. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Daniel G. Schultz, M.D.

Director

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure


510(k) Number (if known): K021994

Device Name: Bard® CONFORMEXX™ Biliary Stent and Delivery System

FDA's Statement of the Indications For Use for device:

The Bard® CONFORMEXX™ Biliary Stent and Delivery System is indicated for use in the treatment of biliary strictures resulting from malignant neoplasms.

Prescription Use  OR Over-The-Counter Use   
(Per 21 CFR 801.109)

  
**(Division Sign-Off)**  
**Division of Reproductive, Abdominal,**  
**and Radiological Devices**  
510(k) Number K021994